JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.63B |
| 2 |
JPMorgan BetaBuilders Japan ETF
BBJP
|
+$1.83B |
| 3 |
JPMorgan BetaBuilders International Equity ETF
BBIN
|
+$1.55B |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$1B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$884M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI EAFE ETF
IEFA
|
+$1.8B |
| 2 |
iShares MSCI EAFE ETF
EFA
|
+$1.77B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$884M |
| 4 |
iShares Core US Aggregate Bond ETF
AGG
|
+$880M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$834M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.09% |
| 2 | Technology | 16.19% |
| 3 | Financials | 10.76% |
| 4 | Healthcare | 10.54% |
| 5 | Consumer Discretionary | 10.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2301
Columbus McKinnon
CMCO
$488M
| $5.35M | ﹤0.01% |
159,831
+21,307
| +15% | +$588K |
2013 Q2
28 quarters
|
|
2302
CALL
Starbucks
SBUX
$108B
| $5.33M | ﹤0.01% |
72,500
-40,000
| -36% | -$3.01M |
2016 Q1
17 quarters
|
|
|
ARR
2303
Armour Residential REIT
ARR
$1.91B
| $5.33M | ﹤0.01% |
113,578
-5,353
| -5% | -$224K |
2015 Q3
19 quarters
|
|
2304
PUT
CME Group
CME
$97.8B
| $5.32M | ﹤0.01% |
32,700
-90,000
| -73% | -$16.1M |
2017 Q4
10 quarters
|
|
|
XRN
2305
Chiron Real Estate Inc
XRN
$451M
| $5.31M | ﹤0.01% |
93,685
+13,799
| +17% | +$749K |
2017 Q4
10 quarters
|
|
2306
CALL
AstraZeneca
AZN
$244B
| $5.29M | ﹤0.01% |
50,050
+25,050
| +100% | +$2.59M |
2018 Q3
7 quarters
|
|
2307
SiriusPoint
SPNT
$2.9B
| $5.29M | ﹤0.01% |
704,280
-25,767
| -4% | -$195K |
2016 Q4
14 quarters
|
|
2308
Innovative Industrial Properties
IIPR
$1.37B
| $5.27M | ﹤0.01% |
59,893
+7,187
| +14% | +$585K |
2017 Q3
11 quarters
|
|
2309
Phathom Pharmaceuticals
PHAT
$537M
| $5.27M | ﹤0.01% |
160,119
+156,575
| +4,418% | +$6.02M |
2019 Q4
2 quarters
|
|
|
MRSN
2310
DELISTED
Mersana Therapeutics
MRSN
| $5.26M | ﹤0.01% |
9,000
-8,867
| -50% | -$3.03M |
2017 Q2
12 quarters
|
|
|
NVTA
2311
PUT
DELISTED
Invitae Corporation
NVTA
| $5.25M | ﹤0.01% |
173,500
| – | – |
2020 Q1
1 quarter
|
|
|
FVAC.U
2312
DELISTED
Fortress Value Acquisition Corp. Units, each consisting of one share of Class A common stock and one
FVAC.U
| $5.25M | ﹤0.01% |
+509,771
| New | +$5.13M |
2020 Q2
0 quarters
|
|
|
FLXN
2313
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $5.24M | ﹤0.01% |
398,666
+223,754
| +128% | +$2.32M |
2015 Q4
18 quarters
|
|
2314
BGC Group
BGC
$5.84B
| $5.24M | ﹤0.01% |
1,912,050
-994,677
| -34% | -$2.75M |
2013 Q2
28 quarters
|
|
2315
Coherent
COHR
$65.5B
| $5.23M | ﹤0.01% |
110,828
-8,343
| -7% | -$331K |
2013 Q2
28 quarters
|
|
|
MNK
2316
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $5.23M | ﹤0.01% |
1,952,598
+873,289
| +81% | +$2.62M |
2013 Q3
27 quarters
|
|
2317
Levi Strauss
LEVI
$7.87B
| $5.23M | ﹤0.01% |
390,226
+107,246
| +38% | +$1.41M |
2019 Q1
5 quarters
|
|
2318
CALL
State Street Technology Select Sector SPDR ETF
XLK
$132B
| $5.22M | ﹤0.01% |
100,000
| – | – |
2020 Q1
1 quarter
|
|
2319
Sabre
SABR
$787M
| $5.22M | ﹤0.01% |
647,207
+90,867
| +16% | +$644K |
2014 Q2
24 quarters
|
|
|
GRA
2320
DELISTED
W.R. Grace & Co.
GRA
| $5.22M | ﹤0.01% |
102,692
+69,501
| +209% | +$3.29M |
2013 Q2
28 quarters
|
|
|
BERY
2321
DELISTED
Berry Global Group, Inc.
BERY
| $5.21M | ﹤0.01% |
127,927
+41,591
| +48% | +$1.56M |
2015 Q4
18 quarters
|
|
|
TRHC
2322
PUT
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $5.19M | ﹤0.01% |
94,900
| – | – |
2020 Q1
1 quarter
|
|
2323
CALL
Sony
SONY
$139B
| $5.18M | ﹤0.01% |
375,000
| – | – |
2019 Q1
5 quarters
|
|
|
2324
PUT
Sony
SONY
$139B
| $5.18M | ﹤0.01% |
375,000
| – | – |
2019 Q1
5 quarters
|
|
|
CSW
2325
CSW Industrials
CSW
$4.91B
| $5.18M | ﹤0.01% |
74,933
-47,407
| -39% | -$3.2M |
2017 Q4
10 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2020 Portfolio in Review
As of Q2 2020, JP Morgan Chase held 5,976 positions worth $518B, up 22% from $426B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q2 2020 filing shows 640 new, 2,055 increased, 2,340 reduced and 398 closed positions. Its largest new stake was JPMorgan BetaBuilders International Equity ETF: 35,626,738 shares worth $1.64B. The largest sale was iShares Core MSCI EAFE ETF, an estimated $1.8B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 28% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2020 buy was JPMorgan BetaBuilders International Equity ETF: 35,626,738 shares worth $1.64B.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q2 2020, an estimated $2.63B increase.
- JP Morgan Chase's biggest Q2 2020 reduction was iShares Core MSCI EAFE ETF, cutting an estimated $1.8B.
- JP Morgan Chase fully exited Allergan plc in Q2 2020, selling an estimated $656M.
- JP Morgan Chase's ten largest holdings make up 17% of its $518B portfolio in Q2 2020.
- JP Morgan Chase opened 640 new positions and closed 398 in Q2 2020.
- JP Morgan Chase's portfolio value rose 22% quarter-over-quarter to $518B.
Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.